Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Thonburi Healthcare Group Public Company Limited (THG.BK)
Bangkok, TH
Thonburi Healthcare Group Public Company Limited, alongside its affiliated entities, manages private hospitals throughout Thailand. The company's operations are divided into three primary segments: Medical Services, Healthcare Solution Provision, and Other Businesses. It offers a comprehensive range of medical treatments, encompassing specialized care in neurosciences, orthopedics, gastroenterology, cardiology, and obstetrics and gynecology. Additionally, the group provides management expertise for provincial government hospitals and heart centers across both public and private sectors. Its varied business interests also include offering elder care and senior living facilities, in-home healthcare services, and operating patient rehabilitation centers. Furthermore, the company engages in real estate development for senior housing, oversees elderly care facilities, and distributes a wide array of dental supply brands such as Adec, W&H, AO, Heraeus, Ivoclar, Megagen, SAM, Melag, and Alpro. Other ventures involve the retail sale of pharmaceuticals and medical supplies in specialized outlets, the creation of hospital management software, and broader property development. Thonburi Healthcare Group operates a network of hospitals that includes four facilities in or near Bangkok (Thonburi, Thonburi 2, Thonburi Bamrungmuang, and Thonburi Burana Hospital in Pathum Thani), four provincial hospitals (Rajyindee, Ubonrak Thonburi, Sirivej Chanthaburi, and Thonburi Thungsong), and one international hospital located in the Republic of the Union of Myanmar. Founded in 1976, the company maintains its headquarters in Bangkok, Thailand.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.34% | -5.03% | -13.71% | -16.57% | -1.31% | -11.70% | -11.70% | -87.48% | -65.93% | -77.58% | -77.58% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%-4.0% Q1'26: -3.5% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%+103.9% ★ Q1'26: -2.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+1.8% Q1'26: +6.3% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+3.5% Q1'26: +2.4% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+1.1% Q1'26: +0.7% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+39.0% Q1'26: +111.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×2.66× Q1'26: 2.80× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6.61B
est: 6.60B (+0.2%)
|
7.09B
est: 7.08B (+0.2%)
|
8.23B
est: 8.06B (+2.2%)
|
7.31B
est: 7.32B (0.0%)
|
10.85B
est: 10.01B (+8.4%)
|
11.54B
est: 11.57B (-0.3%)
|
9.84B
est: 9.49B (+3.7%)
|
9.48B
est: 9.98B (-5.0%)
|
9.10B
est: 9.08B (+0.2%)
|
9.44B
9.11B – 9.77B
+4.0% YoY
|
9.70B
9.06B – 10.34B
+2.7% YoY
|
9.98B
9.63B – 10.32B
+2.9% YoY
|
| EBITDA |
1.13B
est: 1.18B (-4.7%)
|
1.05B
est: 1.27B (-16.8%)
|
1.11B
est: 1.44B (-22.8%)
|
1.10B
est: 1.31B (-16.1%)
|
2.92B
est: 1.79B (+62.8%)
|
3.13B
est: 2.07B (+51.2%)
|
2.08B
est: 1.72B (+20.7%)
|
-60.30M
est: 1.81B (-103.3%)
|
1.47B
est: 1.65B (-10.5%)
|
1.71B
1.65B – 1.77B
+4.0% YoY
|
1.76B
1.64B – 1.88B
+2.7% YoY
|
1.81B
1.75B – 1.87B
+2.9% YoY
|
| EBIT |
825.03M
est: 485.91M (+69.8%)
|
530.07M
est: 521.64M (+1.6%)
|
469.37M
est: 593.61M (-20.9%)
|
327.64M
est: 538.88M (-39.2%)
|
2.03B
est: 737.25M (+175.4%)
|
2.33B
est: 852.41M (+173.7%)
|
939.36M
est: 694.63M (+35.2%)
|
-1.23B
est: 730.55M (-268.9%)
|
315.85M
est: 664.23M (-52.4%)
|
691.05M
667.06M – 715.04M
+4.0% YoY
|
710.01M
662.96M – 757.06M
+2.7% YoY
|
730.28M
704.93M – 755.63M
+2.9% YoY
|
| Net Income |
553.84M
est: 454.22M (+21.9%)
|
347.60M
est: 369.40M (-5.9%)
|
462.39M
est: 329.20M (+40.5%)
|
22.81M
est: 46.37M (-50.8%)
|
1.34B
est: 957.03M (+39.7%)
|
1.60B
est: 1.47B (+9.3%)
|
295.41M
est: 7.22M (+3,990.9%)
|
-1.76B
est: 115.27M (-1,630.7%)
|
96.22M
est: 96.22M (+0.0%)
|
282.72M
269.96M – 295.48M
+193.8% YoY
|
414.00M
343.85M – 928.39M
+46.4% YoY
|
1.11B
1.06B – 1.16B
+167.5% YoY
|
| SGA |
1.01B
est: 1.13B (-11.4%)
|
1.38B
est: 1.22B (+13.1%)
|
1.40B
est: 1.39B (+0.8%)
|
1.40B
est: 1.26B (+11.6%)
|
1.57B
est: 1.72B (-9.1%)
|
1.72B
est: 1.99B (-13.6%)
|
1.81B
est: 1.63B (+10.9%)
|
1.81B
est: 1.72B (+5.4%)
|
1.74B
est: 1.56B (+11.7%)
|
1.62B
1.57B – 1.68B
+4.0% YoY
|
1.67B
1.56B – 1.78B
+2.7% YoY
|
1.72B
1.66B – 1.78B
+2.9% YoY
|
| EPS |
0.72
est: 0.54 (+34.3%)
|
0.41
est: 0.44 (-5.9%)
|
0.54
est: 0.39 (+39.0%)
|
0.03
est: 0.05 (-50.7%)
|
1.59
est: 1.13 (+40.8%)
|
1.89
est: 1.71 (+10.7%)
|
0.35
est: 0.01 (+5,609.6%)
|
-2.08
est: 0.10 (-2,225.6%)
|
0.08
est: 0.06 (+47.3%)
|
0.24
0.23 – 0.25
+332.8% YoY
|
0.54
0.29 – 0.79
+125.0% YoY
|
0.94
0.90 – 0.98
+74.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | B | 3/5 | 4/5 | 3/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 4/5 | 3/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 4/5 | 3/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | B | 3/5 | 4/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | T. Rowe Price Small-Mid Cap ETF TMSL | 0.68% | 18.72M | 0.55% |
| 2 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 65.4K | 0.65% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 25.3K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 57.0K | 0.26% |
| 5 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 4.5K | 0.22% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 13.6K | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 7.3K | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 3.2K | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 372.80 | 0.22% |
| 10 | Vanguard Retirement Income ETF Portfolio VRIF.TO | 0.00% | 122.49 | 0.31% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chalermkul Apibunyopas | Chief Executive Officer of Thonburi Thawiwatthana Hospital, Director & Acting Chief Sustainability Officer | 2M | male |
| Paiboon Eksaengsri | Group Chief Executive Officer & Director | 465.0K | — |
| Nalin Vanasin | Chief Sustainability Officer & Director | 77.3K | female |
| Associate Visit Vamvanij | Chief Executive Officer Thonburi Hospital | 12.7K | — |
| Nattakan Jittinapat | Company Secretary | — | female |
| Hathaichanok Pangnoi | Head of Internal Audit | — | female |
| Pumipat Chatnoraset | Accounting Director | — | male |
| Siripong Luengvarinkul | Chief Executive Officer of Thonburi Hospital, Chief Operating Officer & Director | — | — |
| Vachiraboon Sastararuji | Acting Chief Executive Officer at Thonburi Hospital | — | — |
| Yothika Sripongphankul | Acting Chief Financial Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for THG.BK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
